PlasmonicTron Co. Ltd.
Update：2026/04/10
Industries
Main Industry
Biotechnology
Main Product/Service
Currently focused on retinal organoid development, providing:
Retinal organoid samples suitable for bulk production
Quality validation reports including structural metrics
Retinal organoid samples suitable for bulk production
Quality validation reports including structural metrics
Founded Year
2020
Unified Business No.
83464716
Status
Active
Number of Employees
0
Total Paid-in
Capital
11,600,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PlasmonicTron provides the critical biological infrastructure—industrial-scale Organoids—to power the next decade of biotech innovation and Regenerative Medicine. We solve the industry's primary bottleneck: achieving high-consistency and reliability in organoid bioprocessing. By integrating ML-driven process control and automated cultivation, we transform manual workflows into standardized, regulatory-grade manufacturing. From NAMs-aligned drug screening to advanced scaffolds for regenerative therapies, PlasmonicTron is the industrialized total solution for biopharma and clinical partners seeking to scale biological models and accelerate the future of precision medicine.
